A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome

BACKGROUND: Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABA(B)) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerabili...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biomed J
Autors principals: Girish, K., Vikram Reddy, K., Pandit, Lakshmi V., Pundarikaksha, H.P., Vijendra, R., Vasundara, K., Manjunatha, R., Nagraj, Moulya, Shruthi, R.
Format: Artigo
Idioma:Inglês
Publicat: Chang Gung University 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6138810/
https://ncbi.nlm.nih.gov/pubmed/27105601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bj.2015.09.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars